Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217) Authors: Jaume Capdevila, Virginia Pubul, Urbano Anido, Thomas Walter, Javier Molina‑Cerrillo, Teresa Alonso‑Gordoa, Rocio Garcia‑Carbonero, Maria San‑Roman‑Gil, Belen Llana, Paula Jimenez‑Fonseca, Marta Benavent Viñuales, Catherine Ansquer, Eric Baudin, Come Lepage, Maribel del Olmo‑García, José Carlos Ruffinelli, Amandine Beron, Magalie Haissaguerre, Emmanuel Deshayes, David Taïeb, Sergio Baldari, Maddalena Sansovini, Sara Cingarlini, Angelina Filice, Francesco Panzuto, Rosa Álvarez‑Álvarez, Laurence Lousberg, Frank Aboubakar Nana, Jorge Hernando, Alejando García‑Álvarez, Amparo García‑Burillo, Guillermo Villacampa, Timon Vandamme, Nicola Fazio, Alice Durand Published: 2026 Correction: BMC Cancer 25, 613 (2025) https://doi.org/10.1186/s12885-025-13941-3 Following publication of the original article [1], it has been decided to update the Competing interest to reflect the below changes. Remove “The remaining authors declare that they have no competing interests.” Remove “The remaining authors declare that they have no competing interests.” Add “DT is a co-founder, stakeholder, and Chief Medical Officer (CMO) of SILON Therapeutics.” Add “DT is a co-founder, stakeholder, and Chief Medical Officer (CMO) of SILON Therapeutics.” The original article has been updated. References